Chess, thanks for sharing the Insider Financial ar

Quote:

---

Conclusion

These $10 billion lifts on GILD initially from STAT and now Fauci demonstrate what a solution is worth, but remdesivir is not the solution and will not be the “standard of care” despite what Fauci professed to Meg Tirell today. Investors need to see these results through the proper lens. An antiviral is not the solution. The problem stems from the cytokine storm and that is what is killing people. The change in mortality in these “severely ill” patients is not statistically relevant and will not allay peoples fear of dying. The safety profile of remdesivir is manageable with medication and adjustment to the protocol but does that mean we should treat people with a drug that could debilitate people. There is a trade off for quality of life and there is enough information to rationally say that remdesivir is not going to be a panacea for late stage patients and not doing that great of a job getting people out of the hospitals. Currently only one drug exists that can stop mortality, is virtually devoid of side effects, works in days, and completely quiets the cytokine storm and has 40,000 vials waiting for just one person at the administration to stray away from their love affair with remdesivir. If just one White House Press correspondent asked about leronlimab which is made by CytoDyn Inc. (OTCMKTS: CYDY) then perhaps we can turn the tide of the pandemic. The solution is at hand. Prepared to be outraged that results like this are commonplace yet emergency approval of leronlimab is not at hand.

---